BeiGene Announces Presentations at the European Society for Medical Oncology 2017 Congress

CAMBRIDGE, Mass. and BEIJING, China, Aug. 30, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that it will present updates on its anti-PD-1 antibody BGB-A317 and its PARP inhibitor BGB-290 at the upcoming European Society for Medical Oncology (ESMO) 2017 Congress. The ESMO congress will take place September 8-12, 2017 in Madrid, Spain.

Poster Discussion, Abstract # 368PD

Title: Dose Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activity of BGB-290 in Patients with Advanced Solid Tumors

Presenter: Dr. Jason Lickliter

Poster Discussion Session: Developmental Therapeutics
Date & Time: Saturday, September 9, 2017 at 4:30-6:00 PM, CEST
Location: Alicante Auditorium

Poster Presentations

Date & Time: Monday, September 11, 1:15-2:15 PM CEST
Location: Hall 8

Abstract # 387P: Desai, et al., Preliminary Results from Subsets of Patients (Pts) with Advanced Gastric Cancer (GC) and Esophageal Carcinoma (EC) in a Dose-Escalation/Expansion Study of BGB-A317, an Anti-PD-1 Monoclonal Antibody (mAb).

Abstract # 388P: Horvath, et al., Preliminary Results from a Subset of Patients (Pts) with Advanced Head and Neck Squamous Carcinoma (HNSCC) in a Dose-Escalation and Dose-Expansion Study of BGB-A317, an Anti-PD-1 Monoclonal Antibody (mAb).

Abstract # 389P: Meniawy, et al., Preliminary Results from a Subset of Patients (Pts) with Advanced Ovarian Cancer (OC) in a Dose-Escalation/Expansion Study of BGB-A317, an Anti-PD-1 Monoclonal Antibody (mAb).

Abstract # 420TiP: Johnson, et al., Phase 1b/2 Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide in Patients with Locally Advanced or Metastatic Solid Tumors.

Abstract # 421TiP: Wen, et al., Phase 1b/2 Study to Assess the Clinical Effects of BGB-290 in Combination with Radiation Therapy (RT) and/or Temozolomide (TMZ) in Patients with First-Line or Recurrent/Refractory Glioblastoma.

About BGB-A317

BGB-A317 is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has high affinity and specificity for PD-1. It is differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene have entered into a global strategic collaboration for BGB-A317 for solid tumors.  

About BGB-290

BGB-290 is a potent and highly selective inhibitor of PARP1 and PARP2 with pharmacological properties such as brain penetration and PARP–DNA complex trapping demonstrated in preclinical models. BGB-290 is currently in global clinical development as a monotherapy and in combination with other agents for a variety of solid tumor malignancies.

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding clinical data of BGB-A317 or BGB-290. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; BeiGene's ability to achieve market acceptance in the medical community necessary for commercial success; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct preclinical studies and clinical trials and manufacturing; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Investor/Media Contact

Lucy Li, Ph.D.
+1 781-801-1800
[email protected] 
[email protected]